Information Regarding Clinical Trial

Title	A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
Protocol Number	BBI-DSP7888-201G
Sponsor	Boston Biomedical
Investigator	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
Study Related Phone Numbers	479-587-1700 (24 hours)
Key Points for Study	-Prescreen ICF for required HLA typing to determine eligibility. (This central lab test can be done prior to Screening after obtaining prescreening ICF signature. Results take about 10 days to come back. *Might be a good idea to perform while pt is still receiving chemoradiation) -Radiographic evidence of progression following first recurrence or progression from primary therapy consisting of surgery and chemoradiation -Karnofsky Performance Status (KPS) score of ≥60 -Must be at least 12 weeks from completion of prior RT in order to discriminate pseudo-progression from progression -NO evidence of leptomeningeal spread of tumor OR any hx, presence, or suspicion of metastatic disease extracranially -If pt on dexamethasone, dose may not exceed 4mg/day -NO active autoimmune diseases within 2 years of study enrollment - QTcF must be less than 480 msec - LVEF greater than 40%